Phase I and biodistribution study of recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene and ganciclovir administration in patients with head and neck cancer and other malignant tumors

Cancer Gene Therapy

Volumn 16, Issue 9, 2009, Pages 723-730

  Xu, F ^a,b   Li, S ^a,b   Li, X L ^a,b   Guo, Y ^a,b   Zou, B Y ^a,b   Xu, R ^a,b   Liao, H ^a,b   Zhao, H Y ^a,b   Zhang, Y ^a,b   Guan, Z Z ^a,b   Zhang, L ^a,b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Ganciclovir; Phase I clinical trial; Suicide gene therapy; Thymidine kinase

Indexed keywords

ADENOVIRUS VECTOR; GANCICLOVIR; NEUTRALIZING ANTIBODY; THYMIDINE KINASE; VIRUS ANTIBODY;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHILL; CHINESE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; FEMALE; FIBROSARCOMA; FLU LIKE SYNDROME; GRANULOCYTOPENIA; HEAD AND NECK CANCER; HERPES SIMPLEX VIRUS; HUMAN; HUMORAL IMMUNITY; HYPERTENSION; HYPONATREMIA; HYPOPROTEINEMIA; HYPOTENSION; INJECTION SITE REACTION; LEUKOPENIA; MALE; NASOPHARYNX CARCINOMA; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; SIDE EFFECT; SUICIDE GENE THERAPY; THROMBOCYTOPENIA; VIRUS RECOMBINANT; VIRUS SHEDDING; VOMITING;

ADENOVIRIDAE; ADULT; AGED; ANTIBODIES, VIRAL; ANTINEOPLASTIC AGENTS; CHINA; COMBINED MODALITY THERAPY; FEMALE; GANCICLOVIR; GENE THERAPY; GENETIC VECTORS; HEAD AND NECK NEOPLASMS; HUMANS; INJECTIONS, INTRALESIONAL; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; SIMPLEXVIRUS; THYMIDINE KINASE; TOMOGRAPHY, X-RAY COMPUTED;

ADENOVIRIDAE; SIMPLEXVIRUS;

EID: 68949197421     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2009.19     Document Type: Article

References (15)

1. Harvey BG, Maroni J, O'Donoghue KA, Chu KW, Muscat JC, Pippo AL et al. Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions. Hum Gene Ther 2002; 13: 15-63.
2. Sung MW, Yeh HC, Thung SN, Schwartz ME, Mandeli JP, Chen SH et al. Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: results of a phase I clinical trial. Mol Ther 2001; 4: 182-191.
3. Harvey BG, Hackett NR, El-Sawy T, Rosengart TK, Hirschowitz EA, Lieberman MD et al. Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. J Virol 1999; 73: 6729-6742.
4. Chen SH, Shine HD, Goodman JC, Grossman RG, Woo SL. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci USA 1994; 91: 3054-3057.
5. Thompson TC. In situ gene therapy for prostate cancer. Oncol Res 1999; 11: 1-8.
6. Hall SJ, Mutchnik SE, Chen SH, Woo SL, Thompson TC. Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer. Int J Cancer 1997; 70: 183-187.
7. Hall SJ, Sanford MA, Atkinson G, Chen SH. Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer. Cancer Res 1998; 58: 3221-3225.
8. Nasu Y, Saika T, Ebara S, Kusaka N, Kaku H, Abarzua F et al. Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy. Mol Ther 2007; 15: 834-840.
9. Shirakawa T, Terao S, Hinata N, Tanaka K, Takenaka A, Hara I. et al. Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer. Hum Gene Ther 2007; 18: 1225-1232.
10. Li N, Zhou J, Weng D, Zhang C, Li L, Wang B et al. Adjuvant adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of liver transplantation in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2007; 13: 5847-5854.
11. Chévez-Barrios P, Chintagumpala M, Mieler W, Paysse E, Boniuk M, Kozinetz C et al. Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by ganciclovir. J Clin Oncol 2005; 23: 7927-7935.
12. Sterman DH, Recio A, Vachani A, Sun J, Cheung L, DeLong P et al. Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. Clin Cancer Res 2005; 11: 7444-7453.
13. Alvarez RD, Gomez-Navarro J, Wang M, Barnes MN, Strong TV, Arani RB et al. Adenoviral-mediated suicide gene therapy for ovarian cancer. Mol Ther 2000; 2: 524-530.
14. Sterman DH, Treat J, Litzky LA, Amin KM, Coonrod L, Molnar-Kimber K et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 1998; 9: 1083-1092.
15. Slos P, De Meyer M, Leroy P, Rousseau C, Acres B. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8 (+) T-cell immunity and NK activity. Cancer Gene Ther 2001; 8: 321-332.